Skip to main content

Table 2 Contingency table and ROC analysis results for parameter associations with pCR

From: MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

Parameter

N, pCR

N, non-pCR

pCR correlated statea

ROC AUC

Optim c/o

Sens

Spec

p

MET/CEN7 gain or loss

12

12

high

0.791

50 % cells

0.92

0.67

0.0094

MET/CEN7 gain

12

12

high

0.613

32 % cells

0.58

0.67

0.41

MET/CEN7 loss

12

12

high

0.651

24 % cells

0.50

0.83

0.19

MET/CEN7

12

12

high

0.479

1.10

0.42

0.58

1.0

MET/CEN7

12

12

low

0.547

1.00

0.33

0.75

1.0

Ki-67

15

12

high

726

8 % cells

1.00

0.42

0.0098

MET/CEN7 gain or loss AND Ki-67

12

12

high/high

847b

50 % cells/8 % cells

0.92

0.83

0.0006

PTEN gain

13

12

high

674

58 % cells

0.38

1.00

0.039

  1. Abbreviations: N number of specimens, pCR pathologic complete response, AUC area under curve, Optim c/o optimal cutoff (cutoff producing best combined sensitivity and specificity), Sens sensitivity, Spec specificity, p probability calculated using Fischer’s Exact test on contingency tables generated using optimal cutoff(s) as executed using JMP Statistical Software (SAS, Cary, NC)
  2. aThe parameter state that is associated with pCR in ROC curve and contingency table calculations, for which high state comprises specimens with parameter values equal to or greater than the optimum cutoff and low state comprises specimens with parameter values less than the optimum cutoff
  3. bThe AUC for the combined parameters equals the area under the ROC curve of MET/CEN7 gain or loss plus the additional area under the ROC curve of MET/CEN7 gain or loss, holding cutoff constant at 50 %, combined with Ki-67, varied across all possible cutoffs